Evicenter
P&T meetings

Imlifidase

Kidney transplantation in highly sensitized patients

Manufacturer
Hansa Biopharma
Regulatory submission
BLA submitted December 2025
Last updated
85 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Compatible donor allocation and acceptable mismatch programs

2 evidence topics · 2 sources

European guidance on acceptable mismatch programs

“The Eurotransplant Acceptable Mismatch program should be extended.” (opens the source at this quote in a new tab)

Belgian consensus: Acceptable Mismatch program

“For patients who remain in the AM program for ≥3 y without undergoing transplantation, an additional prioritization strategy has been implemented.” (opens the source at this quote in a new tab)